These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23150502)

  • 1. Addition of highly sensitive troponin T and N-terminal pro-B-type natriuretic peptide to electrocardiography for detection of left ventricular hypertrophy: results from the Dallas Heart Study.
    Martinez-Rumayor AA; de Lemos JA; Rohatgi AK; Ayers CR; Powell-Wiley TM; Lakoski SG; Berry JD; Khera A; Das SR
    Hypertension; 2013 Jan; 61(1):105-11. PubMed ID: 23150502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of N-terminal pro-B-type natriuretic peptide levels to electrocardiography criteria for detection of left ventricular hypertrophy: the ARIRANG study.
    Ahn MS; Yoo BS; Lee JH; Lee JW; Youn YJ; Ahn SG; Kim JY; Lee SH; Yoon J; Park JK; Ahn SV; Choi E
    J Korean Med Sci; 2015 Apr; 30(4):407-13. PubMed ID: 25829808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis).
    Peters MN; Seliger SL; Christenson RH; Hong-Zohlman SN; Daniels LB; Lima JAC; de Lemos JA; Neeland IJ; deFilippi CR
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population.
    Neeland IJ; Drazner MH; Berry JD; Ayers CR; deFilippi C; Seliger SL; Nambi V; McGuire DK; Omland T; de Lemos JA
    J Am Coll Cardiol; 2013 Jan; 61(2):187-95. PubMed ID: 23219305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study).
    Seliger SL; de Lemos J; Neeland IJ; Christenson R; Gottdiener J; Drazner MH; Berry J; Sorkin J; deFilippi C
    JACC Heart Fail; 2015 Jun; 3(6):445-455. PubMed ID: 25982111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Index of Maladaptive Myocardial Remodeling in Hypertension.
    Goh VJ; Le TT; Bryant J; Wong JI; Su B; Lee CH; Pua CJ; Sim CPY; Ang B; Aw TC; Cook SA; Chin CWL
    Circ Cardiovasc Imaging; 2017 Sep; 10(9):e006840. PubMed ID: 28847911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY Trial.
    Hijazi Z; Verdecchia P; Oldgren J; Andersson U; Reboldi G; Di Pasquale G; Mazzotta G; Angeli F; Eikelboom JW; Ezekowitz MD; Connolly SJ; Yusuf S; Wallentin L
    J Am Heart Assoc; 2019 Jan; 8(2):e010107. PubMed ID: 30651032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant left ventricular hypertrophy and risk of cognitive impairment in SPRINT MIND trial.
    Kazibwe R; Ahmad MI; Hughes TM; Chen LY; Soliman EZ
    Am Heart J; 2024 Oct; 276():31-38. PubMed ID: 39067559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community.
    Somaratne JB; Whalley GA; Poppe KK; ter Bals MM; Wadams G; Pearl A; Bagg W; Doughty RN
    Cardiovasc Diabetol; 2011 Apr; 10():29. PubMed ID: 21492425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological, electrical and echocardiographic indices versus cardiac magnetic resonance imaging in diagnosing left ventricular hypertrophy.
    Courand PY; Gaudebout N; Mouly-Bertin C; Thomson V; Fauvel JP; Bricca G; Lantelme P
    Hypertens Res; 2014 May; 37(5):444-51. PubMed ID: 24132010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction.
    Hieda M; Sarma S; Hearon CM; Dias KA; Martinez J; Samels M; Everding B; Palmer D; Livingston S; Morris M; Howden E; Levine BD
    Circulation; 2020 Jan; 141(2):115-123. PubMed ID: 31865771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients.
    Khan IA; Fink J; Nass C; Chen H; Christenson R; deFilippi CR
    Am J Cardiol; 2006 May; 97(10):1530-4. PubMed ID: 16679099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard electrocardiographic criteria for left ventricular hypertrophy in Nigerian hypertensives.
    Dada A; Adebiyi AA; Aje A; Oladapo OO; Falase AO
    Ethn Dis; 2005; 15(4):578-84. PubMed ID: 16259479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrocardiographic diagnosis of left ventricular hypertrophy in aortic valve disease: evaluation of ECG criteria by cardiovascular magnetic resonance.
    Buchner S; Debl K; Haimerl J; Djavidani B; Poschenrieder F; Feuerbach S; Riegger GA; Luchner A
    J Cardiovasc Magn Reson; 2009 Jun; 11(1):18. PubMed ID: 19486532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessed value of high-sensitivity cardiac troponin T for cardiovascular disease among CKD patients.
    Sun L; Tan X; Cao X; Zou J
    Ren Fail; 2016 Jun; 38(5):728-37. PubMed ID: 26984066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal changes of cardiac troponin and inflammation reflect progressive myocyte stretch and likelihood for hypertension in a Black male cohort: The SABPA study.
    Jansen van Vuren E; Malan L; von Känel R; Lammertyn L; Cockeran M; Malan NT
    Hypertens Res; 2019 May; 42(5):708-716. PubMed ID: 30626934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Biomarkers and Imaging for Short-Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults.
    Gore MO; Ayers CR; Khera A; deFilippi CR; Wang TJ; Seliger SL; Nambi V; Selvin E; Berry JD; Hundley WG; Budoff M; Greenland P; Drazner MH; Ballantyne CM; Levine BD; de Lemos JA
    J Am Heart Assoc; 2020 Aug; 9(15):e015410. PubMed ID: 32698652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Left Ventricular Hypertrophy Using Bayesian Additive Regression Trees: The MESA.
    Sparapani R; Dabbouseh NM; Gutterman D; Zhang J; Chen H; Bluemke DA; Lima JAC; Burke GL; Soliman EZ
    J Am Heart Assoc; 2019 Mar; 8(5):e009959. PubMed ID: 30827132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac dysfunction in exacerbations of chronic obstructive pulmonary disease is often not detected by electrocardiogram and chest radiographs.
    Shafuddin E; Chang CL; Cooray M; McAnulty KA; Karalus NC; Lee MHS; Hancox RJ
    Intern Med J; 2019 Jun; 49(6):761-769. PubMed ID: 30324703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening.
    Xanthakis V; Larson MG; Wollert KC; Aragam J; Cheng S; Ho J; Coglianese E; Levy D; Colucci WS; Michael Felker G; Benjamin EJ; Januzzi JL; Wang TJ; Vasan RS
    J Am Heart Assoc; 2013 Nov; 2(6):e000399. PubMed ID: 24200688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.